Offline Showroom in USA
Post Offer Free

China Nilotinib CAS 641571-10-0 AMN 107 Tasigna manufacturer


Gold Index: 89462

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > Nilotinib CAS 641571-10-0 AMN 107 Tasigna

Nilotinib CAS 641571-10-0 AMN 107 Tasigna 

Payment Terms: T/T,L/C,WU 
Place of Origin: Shandong, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C28H22F3N7O
Production Capacity: 50 Klogram/Year
Delivery Date: within 7 days
Molecular Formula: C28H22F3N7O
Molecular Weight: 529.52
Specification: CP/USP/EP
Means of Transport: Ocean,Land,Air
Packing: According to the request of...
Content: 99%
Density: 1.362g/cm3

The use of low doses of nilotinib is being investigated for use for Parkinson's and Alzheimer's disease, as well as for ALS, dementia and Huntington's

Nilotinib(CAS: 641571-10-0)



Molecular Formula


Molecular Weight






Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a small molecule tyrosine kinase inhibitorapproved for the treatment of imatinib-resistant chronic myelogenous leukemia.

Medical uses

It is FDA- (29 October 2007), EMA- (29 September 2009), MHRA- (19 November 2007) and TGA- (17 January 2008) approved for use as a treatment for Philadelphia Chromosome (Ph+)-positive Chronic myelogenous leukaemia. In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib, another tyrosine kinase inhibitor currently used as a first-line treatment. In that study 92% of patients (already resistant or unresponsive to imatinib) achieved a normal white blood cell counts after five months of treatment. The drug carries a black box warning for possible heart complications. The use of low doses of nilotinib is being investigated for use for Parkinson's and Alzheimer's disease, as well as for ALS, dementia and Huntington's disease. Novartis announced on April 11, 2011 that it is discontinuing a Phase III trial of Tasigna® (nilotinib) for investigational use in the first-line treatment of gastrointestinal stromal tumor (GIST) based on the recommendation of an independent data monitoring committee. Interim results showed Tasigna is unlikely to demonstrate superiority compared to Novartis's Glivec® (imatinib)*, the current standard of care in this setting.

skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info


sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: